TARS

Tarsus Pharmaceuticals Inc. (TARS) | Rumor.io

Tarsus Pharmaceuticals

TARS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,364

Bullish sentiment (50-day avg)96%

Price to earnings ratio-48.3

Market capitalization3.6B

Earnings per share-1.07

Dividend yield (TTM)—

Revenue (annual)451.4M

Net income (annual)-66.4M

Social

What share of all stock conversation is about TARS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 4

Tarsus Pharmaceuticals, Inc. ($TARS) recently completed the acquisition of Alkeus Pharmaceuticals, adding a Phase 3 oral investigational therapy for Stargardt's disease to its portfolio.
The company's pipeline now includes programs for ocular rosacea, Lyme prevention, and retinal diseases, with top-line results expected for several Phase 2 and 3 trials in 2027 and 2029.
Tarsus' stock has been trending upward, reaching a new all-time high, with some market participants speculating about its potential value and future growth prospects.

Generated by AI

Sentiment

Of the messages about TARS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	95.65% +2.63	78.76% -11.16
Bearish	0%	0% 0	4.35% -2.63	21.24% +11.16

Oct 29

$TARS has significant short interest, making a potential buyout or earnings report a catalyst for price movement.
Tarsus Pharmaceuticals, Inc. has a good takeout candidate profile, with a product that works and a strong management team, making it an attractive acquisition target.
A buyout price of $2.5B or $3B could be reasonable, with the company's fully diluted shares and RSUs adding up to a valuation of $55.55 or $66.66 per share.

Generated by AI

Topics

Of the messages about TARS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	66.67%	25.64%	18.44%
Announcements	—	33.33%	16.92%	46.2%
Technical Analysis	—	0%	37.44%	23.1%
Earnings	—	0%	1.54%	6.8%
Macro	—	0%	18.46%	4.92%
Controversies	—	0%	0%	0.54%

Community

Of the messages about TARS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	20%	19.05%	84.55%	79.2%
Newcomers	80%	80.95%	15.45%	20.8%

Regulars· Aug 6

Tarsus Pharmaceuticals has acquired Alkeus Pharmaceuticals for up to $800M, adding a late-stage oral therapy for Stargardt disease, a rare eye disorder with no approved treatments.
The acquisition is seen as a strategic move to expand Tarsus' eye care leadership position, with the company's XDEMVY product continuing to grow in sales.
The deal includes an upfront payment of $450M, plus milestones, and is seen as a bold move by the company, with some investors expressing concerns about the dilution of shares and the company's priorities.

Newcomers· Aug 27

Newcomers are excited about Tarsus Pharmaceuticals' potential as a leader in the eyecare industry, citing its recent development of a new blockbuster medication.
The newcomers are optimistic about the company's stock performance, with some expecting it to increase in value as the medication gains traction.
There is a mix of opinions on the company's name change from Tarsus Pharmaceuticals to a new name, with some users questioning the decision and others seeing it as a positive move to rebrand and refresh the company's image.

Generated by AI

News

Goldman Sachs initiates Tarsus Pharmaceuticals stock coverage with buy rating

6d agoInvesting.com

Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing

12d agoYahoo Finance

Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing

Elizabeth Yeu Lin, Chief Medical Officer, on September 04, 2026, sold 13,953 shares in Tarsus Pharma

21d agoYahoo Finance

Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing

Seshadri Neervannan, Chief Operating Officer, on September 04, 2026, sold 4,564 shares in Tarsus Pha

21d agoYahoo Finance

Jefferies raises Tarsus Pharmaceuticals price target on guidance

21d agoInvesting.com

Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD

25d agoInvesting.com

Also Discussed

Investors talking about TARS also mention

#	Name	Attention
1	Mirum Pharmaceuticals, Inc.MIRM	0%0
2	DAWN - Day One Biopharmaceuticals, Inc.	——
3	SWTX - SpringWorks Therapeutics, Inc.	——
4	Xencor Inc.XNCR	0%new
5	Arcutis Biotherapeutics, Inc.ARQT	0%+0
6	Syndax Pharmaceuticals, Inc.SNDX	0%+0
7	Kura Oncology, Inc.KURA	0%+0
8	Kiniksa Pharmaceuticals International, plc Class A Ordinary SharesKNSA	0%0
9	Theravance Biopharma Inc.TBPH	0%new
10	WKME - WalkMe Ltd.	——

Tarsus Pharmaceuticals Inc.

Healthcare
Biotechnology

Tarsus Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on eye care. The company develops and commercializes therapies for diseases of the ocular surface, with its lead product addressing demodex blepharitis, a common eyelid condition caused by Demodex mites. Tarsus Pharmaceuticals also advances additional ophthalmology assets and supports a broader eye-care franchise aimed at treating unmet needs in outpatient and specialist settings. Its business combines drug development, regulatory execution, and commercial distribution, making it an important participant in the ophthalmology and specialty pharmaceuticals market. Headquartered in Irvine, California, Tarsus Pharmaceuticals Inc. concentrates on transforming proven science into targeted treatments for patients and eye-care providers.

Website

Location

17700 Laguna Canyon Road

Irvine, CA, 92618

United States

Social

What share of all stock conversation is about TARS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% +0	0% 0

Sep 4

Tarsus Pharmaceuticals, Inc. ($TARS) recently completed the acquisition of Alkeus Pharmaceuticals, adding a Phase 3 oral investigational therapy for Stargardt's disease to its portfolio.
The company's pipeline now includes programs for ocular rosacea, Lyme prevention, and retinal diseases, with top-line results expected for several Phase 2 and 3 trials in 2027 and 2029.
Tarsus' stock has been trending upward, reaching a new all-time high, with some market participants speculating about its potential value and future growth prospects.

Generated by AI

Sentiment

Of the messages about TARS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% 0	95.65% +2.63	78.76% -11.16
Bearish	0%	0% 0	4.35% -2.63	21.24% +11.16

Oct 29

$TARS has significant short interest, making a potential buyout or earnings report a catalyst for price movement.
Tarsus Pharmaceuticals, Inc. has a good takeout candidate profile, with a product that works and a strong management team, making it an attractive acquisition target.
A buyout price of $2.5B or $3B could be reasonable, with the company's fully diluted shares and RSUs adding up to a valuation of $55.55 or $66.66 per share.

Generated by AI

Topics

Of the messages about TARS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	66.67%	25.64%	18.44%
Announcements	—	33.33%	16.92%	46.2%
Technical Analysis	—	0%	37.44%	23.1%
Earnings	—	0%	1.54%	6.8%
Macro	—	0%	18.46%	4.92%
Controversies	—	0%	0%	0.54%

Community

Of the messages about TARS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	20%	19.05%	84.55%	79.2%
Newcomers	80%	80.95%	15.45%	20.8%

Regulars· Aug 6

Tarsus Pharmaceuticals has acquired Alkeus Pharmaceuticals for up to $800M, adding a late-stage oral therapy for Stargardt disease, a rare eye disorder with no approved treatments.
The acquisition is seen as a strategic move to expand Tarsus' eye care leadership position, with the company's XDEMVY product continuing to grow in sales.
The deal includes an upfront payment of $450M, plus milestones, and is seen as a bold move by the company, with some investors expressing concerns about the dilution of shares and the company's priorities.

Newcomers· Aug 27

Newcomers are excited about Tarsus Pharmaceuticals' potential as a leader in the eyecare industry, citing its recent development of a new blockbuster medication.
The newcomers are optimistic about the company's stock performance, with some expecting it to increase in value as the medication gains traction.
There is a mix of opinions on the company's name change from Tarsus Pharmaceuticals to a new name, with some users questioning the decision and others seeing it as a positive move to rebrand and refresh the company's image.

Generated by AI

Tarsus Pharmaceuticals

Social

Sep 4

Oct 29

Regulars· Aug 6

Newcomers· Aug 27

Goldman Sachs initiates Tarsus Pharmaceuticals stock coverage with buy rating

Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing

Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing

Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing

Jefferies raises Tarsus Pharmaceuticals price target on guidance

Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD

Also Discussed

Tarsus Pharmaceuticals Inc.

Company Information

Location

Goldman Sachs initiates Tarsus Pharmaceuticals stock coverage with buy rating

Tarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC Filing

Tarsus Pharmaceuticals Insider Sold Shares Worth $1,220,885, According to a Recent SEC Filing

Tarsus Pharmaceuticals Insider Sold Shares Worth $387,940, According to a Recent SEC Filing

Jefferies raises Tarsus Pharmaceuticals price target on guidance

Tarsus Pharmaceuticals stock hits all-time high at 85.29 USD

Also Discussed

Social

Sep 4

Oct 29

Regulars· Aug 6

Newcomers· Aug 27